News

Canon has launched new TAVR technology designed to help structural heart programs address increasing procedural demand. No specific clinical data or device specifications were provided in the announcement.

Digest: New imaging or support technology from Canon could enhance procedural efficiency and capacity as TAVR volumes continue to expand across risk categories.

CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

The FDA approved the Autus Size-Adjustable Valve from Edwards Lifesciences, the first pulmonary valve replacement designed to expand with patient growth, reducing repeat surgeries in pediatric congenital heart disease. The pivotal study of 62 patients aged 18 months to 16 years demonstrated 100% freedom from device-related complications at 30 days, no reinterventions at 6 months, and favorable hemodynamics through 1 year with mean RVOT gradients ≤40 mmHg and less than moderate regurgitation.

Digest: This first-in-class balloon-expandable valve (13-22 mm) with polymeric leaflets addresses a critical unmet need in pediatric congenital valve disease by potentially eliminating multiple open-heart surgeries during childhood growth.

The FDA has approved the first pediatric heart valve prosthesis designed to grow with children as they develop. This represents a significant advancement in congenital valve replacement, potentially reducing the number of reoperations required in pediatric patients.

Digest: This approval addresses a critical unmet need in pediatric structural heart disease by eliminating the requirement for multiple valve replacements as children grow, which could substantially reduce surgical burden and improve long-term outcomes.

The FDA approved the Autus Size-Adjustable Valve, the first surgically implanted pulmonary valve designed to expand with pediatric growth, featuring novel polymeric leaflets rather than bioprosthetic tissue. The valve can be initially implanted at 13mm diameter for toddlers and balloon-expanded up to 22mm as the child matures, potentially reducing the need for multiple open-heart reoperations.

Digest: This landmark approval addresses a significant unmet need in congenital heart disease management and introduces a novel biomaterial approach that could influence future pediatric valve development across multiple positions.

The FDA has granted clearance for a video endoscope system intended for use in select minimally invasive cardiac surgical procedures. Specific procedural indications and device specifications were not detailed in the available content.

Digest: Enhanced visualization technology for minimally invasive cardiac surgery may facilitate adoption of less invasive surgical approaches for structural heart interventions, particularly minimally invasive surgical valve repair and replacement.

The FDA cleared an artificial intelligence tool designed to detect undiagnosed valvular heart disease through analysis of standard 12-lead electrocardiograms. The AI algorithm enables screening for structural heart conditions using routine ECG data without requiring echocardiography.

Digest: This screening tool could facilitate earlier identification of valve disease patients who may be candidates for structural heart interventions, potentially expanding the treatable patient population.

Women experience persistent mitral regurgitation following transcatheter aortic valve replacement at higher rates compared to men. This sex-based difference in post-TAVR outcomes suggests potential anatomical or procedural factors affecting mitral valve function differently between sexes.

Digest: Sex-specific differences in post-TAVR complications may influence patient selection, procedural planning, and surveillance protocols for structural heart teams performing TAVR procedures.

A study of 1,114 TAVR patients at Karl Landsteiner University identified sex-specific differences in outcomes related to pacemaker implantation following the procedure. Women showed increased vulnerability immediately after new pacemaker implantation post-TAVR, while pre-existing pacemakers in men were associated with long-term risk.

Digest: These findings suggest that sex-specific risk stratification for conduction abnormalities and pacemaker need should be incorporated into pre-procedural TAVR assessment and post-procedural management, particularly as TAVR expands to younger, lower-risk populations.

Mount Sinai researchers received a $3.6 million, four-year NIH grant to develop EVOLVE-MR, a project linking randomized trial data with Medicare records to extend mitral valve surgery evidence to real-world populations. The study will use machine learning and causal inference methods to determine whether clinical trial benefits persist in broader, more diverse patient groups over longer follow-up periods.

Digest: This research addresses the critical gap between clinical trial populations and real-world mitral regurgitation patients, potentially enabling more individualized surgical decision-making for the 13 million U.S. adults with valvular heart disease.

Patients who wait longer than 6 months to undergo transcatheter aortic valve replacement after indication may experience worse survival outcomes. The study suggests timely TAVR referral and performance is associated with improved mortality rates compared to prolonged delays.

Digest: This finding reinforces the importance of streamlined TAVR referral pathways and may influence heart team decision-making regarding procedural timing and patient selection strategies.

Photon-counting CT has been validated as an accurate screening tool for detecting valve dysfunction in patients who have undergone transcatheter aortic valve replacement. The imaging modality demonstrates improved diagnostic capability for assessing TAVR valve performance during follow-up.

Digest: Advanced imaging tools that can reliably detect early TAVR valve dysfunction are critical for optimizing long-term patient management and surveillance strategies as TAVR extends into younger, lower-risk populations.

TCT 2026 conference organizers have announced the slate of late-breaking clinical trials to be presented in San Diego. The announcement indicates which studies will be featured, though specific trial names and data are not yet disclosed.

Digest: Late-breaking trial announcements at TCT typically include pivotal structural heart studies that influence clinical practice and regulatory decisions in the interventional cardiology field.

Medical societies and aging advocacy groups have issued initial responses to new CMS coverage policies affecting transcatheter aortic valve replacement. The policy changes appear to modify reimbursement or coverage criteria for TAVR procedures.

Digest: CMS coverage determinations directly impact TAVR access, reimbursement dynamics, and patient selection strategies for structural heart programs nationwide.

Nicklaus Children's Hospital performed one of the first transcatheter Fontan completions in the United States on a 2-year-old child with double-outlet right ventricle, using a catheter-based approach instead of traditional open-heart surgery. The patient recovered well and was discharged home, avoiding additional sternotomy for the final stage of single-ventricle palliation.

Digest: This represents an important expansion of minimally invasive techniques into complex congenital heart disease, potentially establishing a paradigm shift in Fontan completion that could reduce surgical morbidity and recovery time for single-ventricle patients.

CMS finalized a national coverage determination expanding Medicare coverage for transcatheter aortic valve replacement to include asymptomatic patients with severe aortic stenosis. This represents a significant broadening of the Medicare eligible patient population beyond the previous requirement for symptomatic disease.

Digest: This reimbursement expansion substantially increases the addressable market for TAVR and aligns Medicare coverage with current clinical practice patterns and recent trial evidence in asymptomatic severe AS patients.

The FDA has granted clearance for a new embolic protection device designed to capture debris during transcatheter aortic valve replacement procedures. This device aims to reduce the risk of periprocedural stroke by preventing particulate matter from reaching the cerebral circulation during valve deployment.

Digest: Embolic protection devices address a persistent clinical concern in TAVR, as stroke remains a significant complication affecting 1-3% of procedures and impacting patient outcomes and healthcare costs.

New data reveal ongoing concerns about heart failure occurrence both before and after transcatheter aortic valve replacement procedures. The findings highlight persistent clinical challenges in managing heart failure in TAVR patient populations.

Digest: Heart failure remains a critical complication affecting TAVR outcomes and patient selection, with implications for pre-procedural optimization and post-procedural surveillance strategies.

A surgeon completed the first implant of a semi-rigid annuloplasty ring for tricuspid valve repair. No additional clinical details, outcomes, or patient data were provided in the source material.

Digest: Represents a technical milestone in surgical tricuspid valve repair, though clinical significance cannot be assessed without device specifications, patient outcomes, or comparative data.

A cardiac surgeon performed the first US implant of an investigational heart valve device that is currently undergoing FDA review but has not yet received regulatory approval. The procedure represents an early access case under what is likely an FDA early feasibility study or expanded access protocol.

Digest: This signals advancement of a novel valve technology through US regulatory pathways and provides early clinical experience that may inform future FDA approval decisions and market adoption strategies.

Medtronic announced an investment of up to $80 million in Pi-Cardia, a medical technology company, with a potential acquisition option included in the agreement. No specific clinical data or device performance metrics were disclosed in this announcement.

Digest: This strategic investment signals Medtronic's interest in expanding its structural heart portfolio through potential acquisition of Pi-Cardia's technology platform.

Tricuspid valve repair demonstrated major clinical benefits in high-risk patients with significant tricuspid regurgitation. The study showed improved outcomes in this challenging patient population undergoing intervention.

Digest: Establishes evidence for tricuspid intervention in high-risk cohorts, supporting growing adoption of transcatheter and surgical repair techniques in an underserved valve disease population.

The article addresses the clinical question of optimal sequencing when patients require both transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI). The content explores whether performing PCI before, during, or after TAVR affects procedural outcomes and patient safety.

Digest: Concomitant coronary artery disease is common in TAVR candidates, and determining the optimal revascularization strategy impacts procedural planning, resource allocation, and patient outcomes for interventional cardiologists.

The TRIC-I-HF trial demonstrated that transcatheter tricuspid valve repair plus optimal medical therapy was superior to medical therapy alone in patients with symptomatic severe tricuspid regurgitation and heart failure. The intervention reduced all-cause death and HF hospitalization with benefits emerging early and sustained to 3 years, along with meaningful quality of life improvements.

Digest: This represents the first time transcatheter tricuspid repair has shown significant reductions in hard clinical endpoints (mortality and HF hospitalization), not just quality of life, potentially establishing a new standard of care for severe tricuspid regurgitation patients.

The phase 3 LIBREXIA trial evaluating milvexian, an oral factor XIa inhibitor, was halted early for futility in patients with recent acute coronary syndrome at high risk for recurrent ischemic events. Milvexian added to antiplatelet therapy did not reduce cardiovascular death, MI, or ischemic stroke compared with placebo, though no excess bleeding risk was observed.

Digest: This trial demonstrates that factor XIa inhibition does not provide additional ischemic protection in ACS patients on antiplatelet therapy, though the lack of bleeding signal may inform ongoing anticoagulation strategies in structural heart interventions where thrombotic and hemorrhagic balance is critical.

An analysis found no significant sex-based differences in timing of care for patients undergoing mitral transcatheter edge-to-edge repair (M-TEER). The study suggests that male and female patients receive similarly timed treatment access and procedural care.

Digest: Demonstrates equity in care delivery for M-TEER procedures across sexes, addressing ongoing concerns about potential gender disparities in access to advanced structural heart interventions.

A new risk scoring system has been developed to predict poor functional outcomes in older patients undergoing transcatheter aortic valve replacement. The score aims to improve patient selection and prognostication beyond traditional mortality risk assessments.

Digest: This tool could help structural heart teams better identify elderly TAVR candidates at risk for diminished quality of life or functional decline post-procedure, potentially improving shared decision-making and patient selection.

A study reports early positive outcomes in patients undergoing redo transcatheter aortic valve replacement procedures using self-expanding valve prostheses. The findings suggest self-expanding valves may be a viable option for treating failed prior TAVR procedures.

Digest: This addresses a growing clinical challenge as the first generation of TAVR patients develop structural valve deterioration requiring reintervention, informing valve selection strategies for redo procedures.

A New York health system filed a lawsuit against another health system over cardiology services, escalating competition for cardiovascular care delivery in the region. The legal dispute prompted state legislators to introduce new legislation addressing healthcare service agreements and competition.

Digest: Litigation over cardiology service lines reflects intensifying competition for structural heart programs, which may impact referral patterns, program consolidation, and access to TAVR and other interventional procedures in competitive markets.

A study demonstrates that transcatheter aortic valve replacement is safe in patients with large aortic annuli. Heart failure complications remain an area of concern in this patient population.

Digest: Expands evidence for TAVR applicability in anatomically challenging cases with larger annular dimensions, though persistent heart failure risk may influence device selection and patient management strategies.

New data demonstrate superior outcomes for surgical aortic valve replacement (SAVR) compared to transcatheter aortic valve replacement (TAVR) in younger patients with aortic stenosis. The findings reinforce current clinical guidance favoring surgery over TAVR in younger, lower-risk patient populations.

Digest: These results support treatment allocation strategies and reinforce age-based selection criteria that impact procedural volumes and market share between TAVR platforms and surgical valve programs.

An AI-powered opportunistic screening tool is being developed to identify patients with undiagnosed aortic stenosis using existing imaging data. The technology aims to detect asymptomatic or unrecognized cases by analyzing routine medical scans that were performed for other clinical indications.

Digest: Early detection of aortic stenosis through opportunistic AI screening could identify intervention candidates before symptom onset, potentially improving outcomes and expanding the patient pool for TAVR and SAVR procedures.

Banner Health is partnering with physicians to expand cardiovascular procedures in ambulatory surgery centers. The initiative aims to shift appropriate heart procedures from hospital-based settings to lower-cost ASC environments.

Digest: ASC migration of structural heart procedures could impact reimbursement models and site-of-service strategies as health systems seek cost reduction while maintaining quality outcomes.

Ventripoint Diagnostics is expanding subscription-based access to its FDA-cleared VMS+ 4.0 platform, which uses AI and Knowledge Based Reconstruction technology to generate MRI-comparable 3D volumetric measurements of all four cardiac chambers from standard echocardiographic images. The company is implementing a Device-as-a-Service model targeting approximately 80% subscription-based adoption to reduce capital budget barriers for hospital implementation.

Digest: This AI-powered echocardiographic platform addresses a critical need for accurate right ventricular volumetric assessment without requiring MRI, with subscription pricing potentially lowering adoption barriers for structural heart programs evaluating patients for interventions.

ASCEND Cardiovascular and Epsilon Imaging announced a strategic partnership integrating ASCEND's enterprise structured reporting platform with Epsilon's EchoInsight Zero Footprint advanced echo analysis system featuring speckle-tracking strain imaging. The integrated solution uses AI-based view classification and bidirectional data exchange to automate strain measurement workflow, generating over 100 standardized measurements based on ASE chamber quantification guidelines without manual data entry.

Digest: Automated strain imaging integration addresses a key workflow barrier to routine use of global longitudinal strain for cardiotoxicity monitoring, heart failure assessment, and valvular disease management in structural heart programs.

Cardiologists have developed a novel anchoring technique to address challenging anatomical scenarios in transcatheter aortic valve replacement procedures. The technical innovation aims to improve procedural outcomes in complex TAVR cases where conventional deployment methods may be inadequate.

Digest: Procedural technique refinements for anatomically challenging cases may expand TAVR eligibility and reduce complications in high-risk subgroups such as those with hostile anatomy or severe calcification.

Emerging developments in cardiac CT include artificial intelligence-driven preventive imaging strategies and noncontrast imaging techniques. These advances aim to expand cardiac CT's clinical utility beyond current anatomical assessment capabilities.

Digest: Enhanced cardiac CT capabilities could improve preprocedural planning for structural heart interventions and risk stratification without contrast-related complications.

Incidental findings on pre-procedural CT scans demonstrate predictive value for mortality following transcatheter aortic valve replacement. The study suggests that non-cardiac imaging findings identified during routine TAVR planning may provide additional risk stratification capabilities.

Digest: Integration of incidental CT findings into TAVR risk assessment models could improve patient selection and prognostic accuracy beyond traditional cardiac risk scores.

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

An expert panel discussion examined current state and future directions of transcatheter aortic valve replacement technology and clinical practice. The panel format suggests coverage of evolving TAVR techniques, patient selection, and emerging challenges in the field.

Digest: Panel discussions at this stage of TAVR adoption typically address unresolved clinical questions around patient selection, durability, and expansion into lower-risk populations that guide practice patterns.

Economic analysis suggests early transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis may be cost-effective compared to watchful waiting. The cost savings would accrue from preventing heart failure hospitalizations and complications associated with delayed intervention.

Digest: This health economics data could influence coverage decisions and clinical practice patterns by supporting intervention before symptom onset in severe AS patients.

New data from the PARTNER 3 trial demonstrate early clinical benefits of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in low-risk patients. The updated analysis reinforces TAVR's favorable early outcomes in this patient population.

Digest: These findings support expanding TAVR utilization in low-risk surgical candidates and may influence treatment algorithms and guideline recommendations for aortic stenosis management.

The U.S. Department of Justice charged 455 defendants, including 90 physicians and licensed healthcare professionals, with over $6.5 billion in alleged Medicare and Medicaid fraud in a 2026 national enforcement sweep. Healthcare law experts emphasize the need to distinguish between intentional fraud and honest billing mistakes resulting from complex regulatory requirements, as federal investigations continue with CMS deferring over $1 billion in Medicaid payments pending documentation review.

Digest: Heightened federal fraud enforcement and compliance scrutiny may impact structural heart practices through increased billing audits, reimbursement delays, and pressure to document medical necessity for high-cost procedures like TAVR and mitral interventions.

Abbott has initiated the Treat TR study, a post-market study enrolling approximately 1,000 patients across up to 100 sites in the U.S., Canada, and Europe to evaluate the safety and performance of the TriClip transcatheter edge-to-edge repair system for tricuspid regurgitation in real-world settings. Patients will be followed for five years, with a sub-study examining the system's potential to reverse cardiac remodeling.

Digest: This large-scale real-world evidence study will provide critical post-market performance data for TriClip TEER, informing adoption decisions and potentially expanding treatment paradigms for TR in clinical practice.

A biomarker enzyme ratio shows potential for predicting stroke and atrial fibrillation risk following transcatheter aortic valve replacement. The diagnostic tool could enable cardiologists to identify high-risk TAVR patients requiring enhanced monitoring or prophylactic intervention.

Digest: Risk stratification biomarkers for post-TAVR cerebrovascular and arrhythmic complications could improve patient selection, personalize antithrombotic strategies, and reduce adverse events in an expanding TAVR population.

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

HOPPR launched its fifth AI foundation model, the EF Chest CT Narrative Model, which processes 3D chest CT volumes to generate narrative reports across pulmonary, mediastinal, cardiac, upper abdominal, osseous, and soft tissue regions. The model was trained on a large proprietary U.S. dataset with deliberate overrepresentation of serious conditions including aortic injury, pulmonary embolism, rib fractures, and pneumothorax.

Digest: This AI model offers potential automated assessment of cardiac and aortic anatomy on chest CT, which could support preprocedural planning and screening for structural heart interventions, though clinical validation data were not provided.

ElectroWire Medical received FDA 510(k) clearance for the LightningWire Transseptal Puncture System, a novel electrosurgical guidewire designed to create atrial septal defects for left-sided cardiac procedures. The 0.032-inch diameter system features proprietary insulation enabling low-power transseptal puncture while providing stiffness comparable to 0.035-inch guidewires, with compatibility across existing electrosurgical generators and transseptal introducers.

Digest: This device addresses a critical access step for multiple structural heart procedures including TMVR, LAAO, and atrial fibrillation ablation, potentially improving procedural efficiency and reducing costs through platform-agnostic compatibility.

A new study examines failure to rescue rates following transcatheter aortic valve replacement (TAVR) procedures, comparing outcomes between high-volume and low-volume hospital centers. The analysis focuses on hospital-level differences in mortality following post-procedural complications.

Digest: Failure to rescue metrics may inform hospital volume-outcome relationships and quality benchmarking for TAVR programs, with implications for center credentialing and patient referral patterns.

A study found that less invasive anesthesia strategies during transcatheter aortic valve replacement are associated with improved clinical outcomes. The use of conscious sedation or local anesthesia instead of general anesthesia during TAVR procedures demonstrated a key benefit for patients.

Digest: Anesthesia strategy optimization represents a modifiable procedural factor that can improve TAVR outcomes and potentially reduce costs without requiring changes to valve technology or operator technique.